Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy
NCT04125329Phase 1Unknown
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
- Start
- Apr 2020
- Primary completion
- Sep 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in diabetic nephropathy (DN), sponsored by Yan'an Affiliated Hospital of Kunming Medical University. Primary endpoint: Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events at 60 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04125329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04125329.